Effect of LDL-apheresis on Pentraxin3 Plasma Levels in Hypercholesterolemic Patients With Coronary Artery Disease
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- acute change in PTX3 plasma values
研究概览
简要总结
Inflammation plays a major role in atherosclerosis. Pentraxin 3 (PTX3) a multifunctional pattern-recognition protein, is expressed in many tissues/cells, including innate immunity cells, endothelium and atherosclerotic plaques. Its role is controversial: it may exert protective cardiovascular effects and/or it may be an indicator of plaque vulnerability and future cardiovascular risk.
LDL-Apheresis removes apoB100-containing lipoproteins and it can prevent progression of coronary artery disease (CAD). LDL-Apheresis exerts non-lipidic beneficial effects on the procoagulatory state and on hemorheology. No data exist about the effects of LDL-Apheresis on plasma PTX3 levels.
详细描述
Hypercholesterolemic patients with documented CAD, on chronic fortnightly LDL-apheresis treatment will be enrolled in this study.
Blood samples will be collected before and after a single LDL-Apheresis treatment to asses PTX3, HsCRP, IL6, IL10, Fibrinogen and lipid plasma levels.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Hypercholesterolemia
- •documented CAD
- •chronic LDL-apheresis treatment
排除标准
- •mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
结局指标
主要结局
acute change in PTX3 plasma values
时间窗: before and at the end of one LDL-apheresis treatment (about 6 hours)
blood samples will be collected before and after a single LDL-apheresis treatment
次要结局
- acute change in hsCRP(before and at the end of one LDL-apheresis treatment (about 6 hours))
- acute change in IL6 and IL10(before and at the end of one LDL-apheresis treatment (about 6 hours))
研究者
Maria Grazia Zenti
principal investigator
Universita di Verona